Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.

Zhang, Jing; Zhang, Peng; Xu, Qiu-Yun; Zhu, Yan-Ting; Chen, Wen; Ji, Chao

Zhang, Jing; Zhang, Peng; Xu, Qiu-Yun; Zhu, Yan-Ting; Chen, Wen; Ji, Chao.

Afiliação

Zhang J; Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Zhang P; Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Xu QY; Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Zhu YT; Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Chen W; Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Ji C; Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.

Australas J Dermatol ; 63(1): e71-e74, 2022 Feb.

Article em En | MEDLINE | ID: mdl-34463968

Assuntos

Anticorpos Monoclonais Humanizados/efeitos adversos; Antineoplásicos Imunológicos/efeitos adversos; Poroceratose/induzido quimicamente; Síndrome de Stevens-Johnson/etiologia; Adulto; Carcinoma Hepatocelular/tratamento farmacológico; Humanos; Neoplasias Hepáticas/tratamento farmacológico; Masculino

Palavras-chave

PD-1 inhibitor; Stevens-Johnson syndrome; immune checkpoint inhibitors; pembrolizumab; porokeratosis; toxic epidermal necrolysis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome de Stevens-Johnson / Poroceratose / Anticorpos Monoclonais Humanizados / Antineoplásicos Imunológicos Tipo de estudo: Risk_factors_studies Limite: Adult / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google